gavel_istock-517976804_avosb-
Avosb / iStockphoto.com
11 August 2017Americas

Federal Circuit rejects Amgen biosimilar discovery request

The US Court of Appeals for the Federal Circuit has rejected a request by Amgen to compel discovery from Hospira over a biosimilar.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
26 September 2017   Amgen has secured $70 million in damages from a jury in a biosimilar dispute with Hospira.
Americas
2 October 2017   Hospira has appealed against a verdict which saw Amgen secure $70 million in damages over a biosimilar dispute between the two companies.

More on this story

Americas
26 September 2017   Amgen has secured $70 million in damages from a jury in a biosimilar dispute with Hospira.
Americas
2 October 2017   Hospira has appealed against a verdict which saw Amgen secure $70 million in damages over a biosimilar dispute between the two companies.

More on this story

Americas
26 September 2017   Amgen has secured $70 million in damages from a jury in a biosimilar dispute with Hospira.
Americas
2 October 2017   Hospira has appealed against a verdict which saw Amgen secure $70 million in damages over a biosimilar dispute between the two companies.